tradingkey.logo
tradingkey.logo
Pesquisar

Myriad Genetics Inc

MYGN
Adicionar à lista de desejos
5.990USD
-0.010-0.17%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
565.46MValor de mercado
PerdaP/L TTM

Mais detalhes de Myriad Genetics Inc Empresa

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Informações de Myriad Genetics Inc

Código da empresaMYGN
Nome da EmpresaMyriad Genetics Inc
Data de listagemOct 06, 1995
CEORaha (Samraat S)
Número de funcionários2700
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 06
Endereço322 North 2200 West
CidadeSALT LAKE CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal84116
Telefone18015843600
Sitehttps://myriad.com/
Código da empresaMYGN
Data de listagemOct 06, 1995
CEORaha (Samraat S)

Executivos da empresa Myriad Genetics Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
93.72K
-36.29%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
86.18K
-135.01%
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
59.05K
+8.47%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
21.32K
-1299.87%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Heiner Dreismann, Ph.D.
Dr. Heiner Dreismann, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
93.72K
-36.29%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
86.18K
-135.01%

Perguntas frequentes

Quem são os cinco principais acionistas de Myriad Genetics Inc?

Os cinco principais acionistas de Myriad Genetics Inc são: Mr. Mark S. Verratti

Quantas instituições possuem ações da Myriad Genetics Inc (MYGN)?

Em 2026Q1, 539 instituições possuíam ações da Myriad Genetics Inc, com valor de mercado aproximado de 102.95M, representando 109.00% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -7290509.00.

Qual é a maior fonte de receita da Myriad Genetics Inc?

Em 2026Q1, o segmento de negócios Hereditary Cancer gerou a maior receita para Myriad Genetics Inc, totalizando 372.40M e representando 45.17% da receita total.